Kiniksa Pharmaceuticals International, plc
Rank #28HypergrowthKNSA · Nasdaq · Healthcare
Kiniksa Pharmaceuticals International, plc (KNSA) — Rank #28 by gross profitability (GP/assets 0.73) · ROE 9.7% · Piotroski F-Score 7 / 9.
As-of 2026-09-15 · CIK 0001730430 · all metrics point-in-time as of the filing date.
About
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally.
Show moreShow less
The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024.
Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- Filer Category
- Large accelerated filer
- Fiscal Year End
- December 31
- Website
- kiniksa.com
Financials
Each fiscal year is read as-of that year’s own 10-K filing, so nothing restated after the fact leaks backwards. Line items this filer never tagged are omitted. Hover or tap a badge for the diagnostic behind it.
| Fiscal year end | 2025-12-31filed 2026-02-24 | 2024-12-31filed 2025-02-25 | 2023-12-31filed 2025-02-25 | 2022-12-31filed 2025-02-25 |
|---|---|---|---|---|
| Revenue | 677.6 | 423.2 | 270.3 | 220.2 |
| Revenue growth (YoY) | 60.1% | 56.6% | 56.6% | 56.6% |
| Cost of revenue | 77.7 | 60.9 | 33.4 | 22.9 |
| Gross profit | 599.9 | 362.3 | 362.3 | 362.3 |
| Gross margin | 88.5% | 85.6% | 85.6% | 85.6% |
| Selling, general & administrative | 196.3 | 168.0 | 129.4 | 98.0 |
| Research & development | 96.9 | 111.6 | 76.1 | 65.5 |
| Operating income | 77.2 | (45.6) | (25.2) | 9.8 |
| Operating margin | 11.4% | -10.8% | -10.8% | -10.8% |
| Interest income | 11.6 | 9.0 | 8.2 | 1.2 |
| Pre-tax income | 88.9 | (36.2) | (16.7) | 11.0 |
| Income tax expense | 29.9 | 7.0 | (30.7) | (172.3) |
| Net income | 59.0 | (43.2) | 14.1 | 183.4 |
| Net margin | 8.7% | -10.2% | -10.2% | -10.2% |
| EPS (basic) | $0.80 | -$0.60 | $0.20 | $2.64 |
| EPS (diluted) | $0.75 | -$0.60 | $0.20 | $2.60 |
Figures are as originally filed with the SEC (point-in-time), not restated, so they can differ slightly from sites that show later-restated numbers. Why point-in-time?